XML 56 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
ACQUISITIONS - Narrative (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Oct. 19, 2015
USD ($)
Oct. 01, 2015
USD ($)
Apr. 01, 2015
USD ($)
product
$ / shares
Feb. 23, 2015
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Oct. 31, 2015
USD ($)
Feb. 10, 2015
USD ($)
Business Acquisition [Line Items]                        
Acquisition-related contingent consideration         $ 170,900,000   $ 196,800,000 $ 170,900,000   $ 196,800,000    
Acquisition of businesses, contingent and deferred consideration obligations at fair value               0 $ 635,800,000      
Purchase price net of cash received               18,500,000 $ 13,885,900,000      
Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date                   24,000,000    
Amoun                        
Business Acquisition [Line Items]                        
Total fair value of consideration transferred $ 911,000,000                      
Acquisition of noncontrolling interest 847,000,000                      
Acquisition-related contingent consideration 75,000,000                      
Acquisition of businesses, contingent and deferred consideration obligations at fair value $ 64,000,000                      
Aggregate purchase price         911,200,000     911,200,000        
Sprout Pharmaceuticals, Inc.                        
Business Acquisition [Line Items]                        
Total fair value of consideration transferred   $ 530,000,000       $ 500,000,000            
Acquisition-related contingent consideration   422,000,000                    
Acquisition of businesses, contingent and deferred consideration obligations at fair value           $ 495,000,000            
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest   1,450,000,000                    
Purchase obligation   200,000,000                    
Commencement trigger, sales revenue   1,000,000,000                    
Aggregate purchase price   $ 1,446,500,000                    
Salix                        
Business Acquisition [Line Items]                        
Total fair value of consideration transferred     $ 13,132,000,000                  
Number of products in product portfolio (more than) | product     20                  
Par value per share of common stock (in dollars per share) | $ / shares     $ 0.001                  
Business Acquisition, Share Price | $ / shares     173.00                  
Aggregate purchase price             13,132,000,000     13,132,000,000    
Range of potential milestone payment, high             650,000,000     650,000,000    
Salix | Restricted Stock                        
Business Acquisition [Line Items]                        
Business Acquisition, Share Price | $ / shares     $ 173.00                  
Other 2015 Acquisitions                        
Business Acquisition [Line Items]                        
Total fair value of consideration transferred                   1,410,000,000    
Acquisition of businesses, contingent and deferred consideration obligations at fair value                   186,000,000    
Aggregate purchase price         1,406,800,000     1,406,800,000        
Dendreon                        
Business Acquisition [Line Items]                        
Acquisition of noncontrolling interest       $ 495,000,000                
Purchase price net of cash received       415,000,000                
Cash received from acquisition       80,000,000                
Stock consideration transferred       $ 50,000,000                
Marathon                        
Business Acquisition [Line Items]                        
Purchase price net of cash received         17,000,000     27,000,000   35,000,000    
Aggregate purchase price                       $ 286,000,000
Assumed liability owed to a third party                       $ 64,000,000
Range of potential milestone payment, high             200,000,000     200,000,000    
Brodalumab [Member]                        
Business Acquisition [Line Items]                        
Upfront payment                     $ 100,000,000  
Brodalumab [Member] | Pre-launch Milestone Payments                        
Business Acquisition [Line Items]                        
Range of potential milestone payment, high         $ 150,000,000   170,000,000 $ 150,000,000   170,000,000    
Brodalumab [Member] | Sales Based Milestone Payments                        
Business Acquisition [Line Items]                        
Range of potential milestone payment, high             175,000,000     $ 175,000,000    
Other (Income) Expense | Amoun                        
Business Acquisition [Line Items]                        
Payments to employees             $ 12,000,000